vs

Side-by-side financial comparison of BridgeBio Pharma, Inc. (BBIO) and PROGRESS SOFTWARE CORP (PRGS). Click either name above to swap in a different company.

PROGRESS SOFTWARE CORP is the larger business by last-quarter revenue ($252.7M vs $154.2M, roughly 1.6× BridgeBio Pharma, Inc.). PROGRESS SOFTWARE CORP runs the higher net margin — 10.2% vs -126.2%, a 136.4% gap on every dollar of revenue. On growth, BridgeBio Pharma, Inc. posted the faster year-over-year revenue change (2521.2% vs 17.5%). PROGRESS SOFTWARE CORP produced more free cash flow last quarter ($59.9M vs $-56.5M).

Brent Saunders is an American biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb. He helped lead various mergers and acquisitions, including the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie. He founded the special-purpose acquisition company (SPAC) Vesper Healthcare Acquisition. Saunders is also executive chairman of medical aesthet...

Progress Software Corporation develops and sells enterprise software products including application development platforms, data connectivity tools, and digital experience solutions. It serves global enterprise clients across finance, healthcare, manufacturing, retail and other sectors, helping organizations build scalable, high-performance business applications and streamline operational workflows.

BBIO vs PRGS — Head-to-Head

Bigger by revenue
PRGS
PRGS
1.6× larger
PRGS
$252.7M
$154.2M
BBIO
Growing faster (revenue YoY)
BBIO
BBIO
+2503.6% gap
BBIO
2521.2%
17.5%
PRGS
Higher net margin
PRGS
PRGS
136.4% more per $
PRGS
10.2%
-126.2%
BBIO
More free cash flow
PRGS
PRGS
$116.4M more FCF
PRGS
$59.9M
$-56.5M
BBIO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BBIO
BBIO
PRGS
PRGS
Revenue
$154.2M
$252.7M
Net Profit
$-194.6M
$25.7M
Gross Margin
94.7%
81.6%
Operating Margin
-90.5%
15.2%
Net Margin
-126.2%
10.2%
Revenue YoY
2521.2%
17.5%
Net Profit YoY
27.2%
2144.6%
EPS (diluted)
$-1.00
$0.59

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BBIO
BBIO
PRGS
PRGS
Q4 25
$154.2M
$252.7M
Q3 25
$120.7M
$249.8M
Q2 25
$110.6M
$237.4M
Q1 25
$116.6M
$238.0M
Q4 24
$215.0M
Q3 24
$178.7M
Q2 24
$175.1M
Q1 24
$211.1M
$184.7M
Net Profit
BBIO
BBIO
PRGS
PRGS
Q4 25
$-194.6M
$25.7M
Q3 25
$-184.9M
$19.4M
Q2 25
$-183.8M
$17.0M
Q1 25
$-169.6M
$10.9M
Q4 24
$1.1M
Q3 24
$28.5M
Q2 24
$16.2M
Q1 24
$-36.2M
$22.6M
Gross Margin
BBIO
BBIO
PRGS
PRGS
Q4 25
94.7%
81.6%
Q3 25
94.6%
81.0%
Q2 25
96.7%
80.1%
Q1 25
97.7%
80.6%
Q4 24
83.0%
Q3 24
83.7%
Q2 24
81.7%
Q1 24
99.7%
82.2%
Operating Margin
BBIO
BBIO
PRGS
PRGS
Q4 25
-90.5%
15.2%
Q3 25
-120.3%
17.6%
Q2 25
-121.4%
16.3%
Q1 25
-89.5%
13.6%
Q4 24
10.0%
Q3 24
22.6%
Q2 24
15.5%
Q1 24
0.2%
19.0%
Net Margin
BBIO
BBIO
PRGS
PRGS
Q4 25
-126.2%
10.2%
Q3 25
-153.2%
7.8%
Q2 25
-166.2%
7.2%
Q1 25
-145.4%
4.6%
Q4 24
0.5%
Q3 24
15.9%
Q2 24
9.2%
Q1 24
-17.1%
12.3%
EPS (diluted)
BBIO
BBIO
PRGS
PRGS
Q4 25
$-1.00
$0.59
Q3 25
$-0.95
$0.44
Q2 25
$-0.95
$0.39
Q1 25
$-0.88
$0.24
Q4 24
$0.01
Q3 24
$0.65
Q2 24
$0.37
Q1 24
$-0.20
$0.51

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BBIO
BBIO
PRGS
PRGS
Cash + ST InvestmentsLiquidity on hand
$570.1M
$94.8M
Total DebtLower is stronger
$2.0B
$1.4B
Stockholders' EquityBook value
$-2.1B
$478.3M
Total Assets
$936.0M
$2.5B
Debt / EquityLower = less leverage
2.93×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BBIO
BBIO
PRGS
PRGS
Q4 25
$570.1M
$94.8M
Q3 25
$643.0M
$99.0M
Q2 25
$756.9M
$102.0M
Q1 25
$540.6M
$124.2M
Q4 24
$118.1M
Q3 24
$232.7M
Q2 24
$190.4M
Q1 24
$519.7M
$133.2M
Total Debt
BBIO
BBIO
PRGS
PRGS
Q4 25
$2.0B
$1.4B
Q3 25
$2.0B
$1.4B
Q2 25
$1.5B
Q1 25
$1.5B
Q4 24
$1.5B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
BBIO
BBIO
PRGS
PRGS
Q4 25
$-2.1B
$478.3M
Q3 25
$-1.9B
$477.7M
Q2 25
$-1.8B
$452.7M
Q1 25
$-1.6B
$431.8M
Q4 24
$438.8M
Q3 24
$425.6M
Q2 24
$401.7M
Q1 24
$-1.0B
$461.7M
Total Assets
BBIO
BBIO
PRGS
PRGS
Q4 25
$936.0M
$2.5B
Q3 25
$998.3M
$2.4B
Q2 25
$1.1B
$2.4B
Q1 25
$881.6M
$2.5B
Q4 24
$2.5B
Q3 24
$1.6B
Q2 24
$1.6B
Q1 24
$849.3M
$1.5B
Debt / Equity
BBIO
BBIO
PRGS
PRGS
Q4 25
2.93×
Q3 25
2.97×
Q2 25
3.22×
Q1 25
3.50×
Q4 24
3.48×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BBIO
BBIO
PRGS
PRGS
Operating Cash FlowLast quarter
$-56.4M
$62.8M
Free Cash FlowOCF − Capex
$-56.5M
$59.9M
FCF MarginFCF / Revenue
-36.6%
23.7%
Capex IntensityCapex / Revenue
0.0%
1.1%
Cash ConversionOCF / Net Profit
2.44×
TTM Free Cash FlowTrailing 4 quarters
$229.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BBIO
BBIO
PRGS
PRGS
Q4 25
$-56.4M
$62.8M
Q3 25
$-109.6M
$73.4M
Q2 25
$-80.7M
$30.0M
Q1 25
$-199.2M
$68.9M
Q4 24
$19.7M
Q3 24
$57.7M
Q2 24
$63.7M
Q1 24
$-219.5M
$70.5M
Free Cash Flow
BBIO
BBIO
PRGS
PRGS
Q4 25
$-56.5M
$59.9M
Q3 25
$-110.0M
$72.4M
Q2 25
$-81.3M
$29.5M
Q1 25
$67.7M
Q4 24
$16.8M
Q3 24
$56.6M
Q2 24
$62.7M
Q1 24
$-220.2M
$70.2M
FCF Margin
BBIO
BBIO
PRGS
PRGS
Q4 25
-36.6%
23.7%
Q3 25
-91.2%
29.0%
Q2 25
-73.5%
12.4%
Q1 25
28.4%
Q4 24
7.8%
Q3 24
31.7%
Q2 24
35.8%
Q1 24
-104.3%
38.0%
Capex Intensity
BBIO
BBIO
PRGS
PRGS
Q4 25
0.0%
1.1%
Q3 25
0.4%
0.4%
Q2 25
0.5%
0.2%
Q1 25
0.0%
0.5%
Q4 24
1.3%
Q3 24
0.6%
Q2 24
0.5%
Q1 24
0.3%
0.2%
Cash Conversion
BBIO
BBIO
PRGS
PRGS
Q4 25
2.44×
Q3 25
3.78×
Q2 25
1.76×
Q1 25
6.30×
Q4 24
17.13×
Q3 24
2.03×
Q2 24
3.93×
Q1 24
3.11×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BBIO
BBIO

Segment breakdown not available.

PRGS
PRGS

Maintenanceand Services$187.5M74%
Share File Acquisition$67.5M27%

Related Comparisons